Review

Time Is Brain: Acute Control of Repetitive Seizures and Status Epilepticus Using Alternative Routes of Administration of Benzodiazepines

Sulaiman Almohaish 1,2, Melissa Sandler 1,3 and Gretchen M. Brophy 1,*

1 Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA; Almohaishsm@vcu.edu (S.A.); sandlerm@vcu.edu (M.S.) 2 College of Clinical Pharmacy, King Faisal University, Al-Ahsa 3398, Saudi Arabia 3 Department of Physical Medicine and Rehabilitation, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA * Correspondence: gbrophy@vcu.edu; Tel.: +1-(804)-828-1201

Abstract: Time plays a major role in seizure evaluation and treatment. Acute repetitive seizures and status epilepticus are medical emergencies that require immediate assessment and treatment for optimal therapeutic response. Benzodiazepines are considered the first-line agent for rapid seizure control. Thus, various routes of administration of benzodiazepines have been studied to facilitate a quick, effective, and easy therapy administration. Choosing the right agent may vary based on the drug and route properties, patient's environment, caregiver's skills, and drug accessibility. The pharmacokinetic and pharmacodynamic aspects of benzodiazepines are essential in the decision-making process. Ultimately, agents and routes that give the highest bioavailability, fastest absorption, and a modest duration are preferred. In the outpatient setting, intranasal and buccal routes appear to be equally effective and more rapidly administered than rectal diazepam. On the other hand, in the inpatient setting, if available, the IV route is ideal for benzodiazepine administration to avoid any potential absorption delay. In this article, we will provide an overview and comparison of the various routes of benzodiazepine administration for acute control of repetitive seizures and status epilepticus.

Keywords: seizure; epilepsy; benzodiazepines; routes of administration; status epilepticus; repetitive seizures; cluster seizures; acute repetitive seizure

1. Introduction

The extent of neurological damage and systemic complications caused by seizures varies based on the duration and frequency of seizures and time to seizure control [1–5]. Healthcare providers and caregivers should promptly recognize and treat acute repetitive seizures and status epilepticus to lower the associated morbidity and mortality [1–6]. Early treatment of acute repetitive seizures, which can lead to status epilepticus, with benzodiazepines is associated with fewer required antiseizure medications upon hospital admission and a shorter seizure duration [7,8]. This emphasizes the importance of readily available agents for rapid seizure termination that can be utilized in both inpatient and outpatient settings.

The goal of seizure treatment is to halt clinical and electrographic seizure activity in the shortest amount of time possible. Different benzodiazepine routes of administration have been studied to determine which route is the fastest and most practical without sacrificing efficacy. Although most emergent seizure treatment strategies have similar clinical efficacy in terms of seizure termination, logistical issues and practicality make some agents more appealing than others. In the case of status epilepticus (SE), after first-line
benzodiazepines are administered, other therapies may be required to control seizures [9–11].

The intravenous (IV) route for medication administration is preferred in patients with an established IV line, but this route is not always achievable, especially in an emergent setting. To overcome this complication, other routes of administration must be considered. The intramuscular (IM) route of administration has a slower onset of action and requires advanced training, but it is a practical and efficacious alternative to the IV route [12,13]. Rectal (PR) administration of drugs permits direct absorption into the bloodstream, leading to a rapid effect without first-pass metabolism [14]. Despite this, rectal administration is typically uncomfortable for patients and the time spent positioning the patient and removing their clothes may delay administration [15,16].

Considering the obstacles associated with these routes of administration, intranasal (IN) and buccal medications have become attractive options, especially in the outpatient setting. Limitations for the IN route include small volume requirements, which may be challenging to accurately measure, and reduced bioavailability due to nasal drainage or congenital abnormalities [17]. The buccal route may be challenging to administer to patients with convulsive seizures due to the risk of finger biting and aspiration.

The pharmacokinetic and pharmacodynamic profiles of benzodiazepines utilized for the treatment of seizures must also be considered. The characteristics of the ideal benzodiazepine are fast onset, an extended duration of action allowing for urgent antiseizure medications to be administered, and no active metabolites. Therefore, the focus of this article is to summarize and highlight benzodiazepine administration strategies and pharmacotherapeutic pearls for the treatment of seizures inprehospital and inpatient settings.

2. Benzodiazepine Routes of Administration and Pharmacotherapeutic Considerations

Lorazepam (manufactured by Baxter Healthcare Corporation, Deerfield, IL, USA.), diazepam (manufactured by Pfizer Inc, New York, NY, USA. Distributed by Hospira Inc, Lake Forest, IL, USA), and midazolam (manufactured by Pfizer Inc, New York, NY, USA. Distributed by Hospira Inc, Lake Forest, IL, USA.) have been widely studied for seizure control. Healthcare clinicians should familiarize themselves with the pharmaceutical differences between these drugs, which will allow them to choose the most appropriate agent for each patient in different scenarios. Knowing which dosage forms are commercially available and which of these agents have a Food and Drug Administration (FDA) approved indication for the type of seizure being treated is also helpful for drug selection (Table 1).

Table 1. Benzodiazepine products, routes, FDA indications, and cost [18–30].

| Agent | Routes of Administration | FDA Indications | Other Considerations | Cost (AWP) |
|-------|--------------------------|-----------------|----------------------|------------|
| Lorazepam | (IV, IM, IN, SL, Oral solution) | IV approved for status epilepticus Other routes used off-label for acute active seizure | IV solution contains propylene glycol IM onset of action is variable [14] SL not available in the US | Ativan®—IV/IM: USD 2.28/2 mg vial Lorazepam—IV/IM: USD 0.60–4/2 mg vial Ativan Intensol®—Oral solution: USD 1.60/2 mg |
| Diazepam | (IV, IM, PR, IN) | IV approved for status epilepticus IV and rectal approved for acute seizure activity IN approved for acute repetitive seizures IM autoinjector approved for the US military use; however, not commercially available | IV solution contains propylene glycol IM onset of action variable [14] | Diazepam—IV/IM: USD 11–16/5 mg Diastat®—PR: USD 421/10 mg Valtoco®—IN: USD 336/5 mg |
Midazolam (IV, IM, buccal, IN) | IN approved for acute repetitive seizures  
Other routes used off-label for status epilepticus or other seizure types  
Buccal not commercially available in the US  
Midazolam—IV/IM: USD 3.43/5 mg  
Nayzilam®—IN: USD 330/5 mg

Clobazam (Oral: tablet, film, susp.) | Approved for Lennox-Gastaut as an adjunctive therapy  
Other indications used off-label for catamenial epilepsy, refractory seizures, and recurrent seizures  
All oral forms are available in the US  
Sympazan®—oral film: USD 17.22/5 mg  
Onfi®—oral suspension: USD 12.67/2.5 mg

AWP—Average wholesale price in the United States. IM, intramuscular; IN, intranasal; IV, intravenous; PR, rectal; Susp, suspension. Ativan® manufactured by MEDA Manufacturing GmbH Cologne, Germany for Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, USA. Ativan Intensol® marketed by Paddock Laboratories Inc, Minneapolis, MN, USA. Lorazepam manufactured by Bayer Healthcare Corporation, Deerfield, IL, USA. Diazepam manufactured by Pfizer Inc, New York, NY, USA and distributed by Hospira Inc, Lake Forest, IL, USA. Diastat® manufactured by DPT Laboratories Ltd, San Antonio, TX, USA for Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, USA. Valtoco® manufactured by Catalent Pharma Solutions, Morrisville, NC, USA. Midazolam manufactured by Pfizer Inc, New York, NY, USA and distributed by Hospira Inc, Lake Forest, IL, USA. Nayzilam® manufactured for Proximagen, LLC, Plymouth, MN, USA. Sympazan® manufactured by Aquestive Therapeutics Warren, NJ, USA. Onfi® manufactured by Rosemont Pharmaceuticals, Ltd. Leeds, West Yorkshire, U.K for Lundbeck, Deerfield, IL, USA.

The IV route of lorazepam is the most widely used for seizure control in the inpatient setting. The IM onset of action is long and its absorption is unpredictable, and the sublingual (SL) tablet is not ideal in moderate to severe cases (Table 1). Diazepam IM administration shares the same absorption issues as IM lorazepam. The IM form of midazolam is absorbed more rapidly and predictably than IM lorazepam or diazepam and, therefore, is recommended in current guidelines [9,10,31] (Table 2).

### Table 2. Benzodiazepine pharmacokinetic and pharmacodynamic characteristics by route of administration [14,18–20,22–26,28–30,32–46].

| Agent | Dose (maximum) | Route | Onset (min) | Duration of Action | Bioavailability (%) | Volume of Distribution (L/kg) | Metabolism | Excretion | T½ (h) |
|-------|----------------|-------|-------------|-------------------|---------------------|-----------------------------|------------|-----------|--------|
| Lorazepam (Ativan® Injection) | 0.1 mg/kg (4 mg) | IV | 1.6 | 4-6 h | 100 | | | | |
| Lorazepam (Ativan Intensol®) | 0.1 mg/kg (4 mg) | SL | Readily | - | 90 | | | | |
| Lorazepam (Ativan® Sublingual tablets) * | 0.1 mg/kg (4 mg) | SL | 15-17 | - | >90 | | | | |
| Midazolam (Versed®) | 0.2 mg/kg (10 mg) | IV | 1.5–2.5 | 30–80 min | 100 | | | | |
| Midazolam (Versed®) | 0.2 mg/kg (10 mg) | IM | 5–15 | 2–6 h | >90 | | | | |
| Midazolam (Nayzilam®) | 0.2 mg/kg (15 mg) | IN | 3–10 | 23 min | 44 | | | | |
| Midazolam | 0.2 mg/kg (15 mg) | IV injection given IN | 6–14 | - | 44–83 | | | | |
| | | | | | | | | | |
| Medicine | Dose | Route | Onset (min) | Duration (min) | CNS Penetration | Metabolism | Elimination |
|----------|------|-------|-------------|---------------|----------------|-----------|-------------|
| Midazolam (Buccolam®, Epistatus®) * | 0.5 mg/kg (30 mg) | Buccal | 5–15 | - | 75–87 | - | - |
| Midazolam (Versed®) | 0.5 mg/kg (30 mg) | IV injection given Buccal | -15 | - | 75 | - | - |
| Diazepam (Valium®) | 0.15 mg/kg (10 mg) | IV | 1–3 | 15–30 min | 100 | CYP2C19 and CYP3A4 to active metabolites | Renal 33–45 |
| Diazepam (Valium®) | - | IM | - | - | >90 | - | - |
| Diazepam (Valium®) | 0.2 mg/kg (20 mg) | IV injection given IN | 1–10 | - | Up to 74 | - | - |
| Diazepam (Diastat®) | 0.2 mg/kg (20 mg) | PR | 2–10 | 15–30 min | 90 | CYP2C19 and CYP3A4 to active metabolites | Renal 46–50 |
| Clobazam (Onfi®) | 0.2 mg/kg (40 mg) | Oral Susp | 19–30 | - | 87 | 100 | - |
| Clobazam (Sympazan®) | 0.2 mg/kg (40 mg) | Oral Film | - | - | - | - | - |

* Not available in the US; IV injectable solution is used for buccal administration in the US; IM, intramuscular; IN, intranasal; IV, intravenous; PR, rectal; Susp, suspension. Ativan® sublingual tablet manufactured by Pfizer Inc, Kirkland, Quebec, Canada. Buccolam® Shire Pharmaceuticals Ireland Limited, Dublin, Ireland. Veriton Pharma, Weybridge, Surrey, UK.

Important pharmacologic characteristics of benzodiazepines for the treatment of seizures and SE are their ability to achieve high central nervous system (CNS) concentrations and their CNS half-life. Diazepam and midazolam cross the blood–brain barrier (BBB) faster than lorazepam, but lorazepam has a longer duration of action in the CNS, resulting in prolonged seizure control (Table 3). These differences may not seem significant, but the additional time allotted to initiate urgent antiseizure medications is beneficial.

Table 3. Central nervous system pharmacokinetic characteristics of benzodiazepines [47–51].

| CNS Characteristics | Lorazepam | Diazepam | Midazolam | Clobazam |
|---------------------|-----------|---------|----------|---------|
| Lipophilicity       | Low       | High    | High     | Low     |
| CNS half-life       | Long      | Short   | Short    | Long    |
| CNS penetration     | Slow      | Fast    | Fast     | Slow    |
| CNS concentration   | 5–15% of serum | 3–12% of serum | 3–14% of serum | 30–34% of serum |
| Onset of EEG slow-wave, minutes | 3.8 ± 3.1 | 0.89 ± 3.1 | 0.29 ± 0.04 | 0.44 ± 0.16 |
| Duration of EEG slow-wave, minutes | 28.3 ± 10.1 | 7.5 ± 1.4 | 6.3 ± 1.9 | 62.7 ± 13.9 |

CNS, central nervous system; EEG, electroencephalogram.

If one benzodiazepine is not available due to limited resources or shortages, comparable doses of another agent should be initiated. Unfortunately, there is limited evidence supporting benzodiazepine dose conversion strategies in patients with seizures, and conversion estimates are usually based on expert opinion and clinical practice.
3. Pharmacokinetic and Pharmacodynamic Properties

All benzodiazepines are γ-aminobutyric acid-A (GABAA) agonists, but differences in their pharmacokinetic profile make each one unique. When considering the use of benzodiazepines for seizure control, it is important to understand each drug’s pharmacokinetic characteristics, including absorption, distribution, metabolism, and excretion, which affect the timing and duration of effect of these agents. Intravenous drugs are 100% bioavailable and have the quickest onset of action, followed by intranasal, rectal, IM, and SL routes of administration for most benzodiazepines. Buccal midazolam (i.e., Buccolam®, Epistatus®) has a similar onset of action to IM midazolam, but its bioavailability is significantly lower than the IM formulation [32–34]. As the buccal formation is not available in the United States, some clinicians use the injectable midazolam solution buccally, which has a comparable bioavailability and onset of action to Buccolam® and Epistatus® [32–34]. Buccal diazepam is under investigation, in phase 3 clinical trials [52].

Regarding the duration of action, both serum and CNS half-lives need to be considered in patients with seizures. The serum half-life of diazepam is longer than that of lorazepam, midazolam and clobazam, but both midazolam and diazepam have short CNS half-lives due to their higher lipophilicity. Lorazepam and clobazam have lower lipophilicity, and lorazepam has an onset of action of 3–5 minutes as compared to diazepam and midazolam, which cross the blood–brain barrier faster (e.g., 1–2 minutes) [47,50,51]. Due to this high lipophilicity, diazepam and midazolam also quickly redistribute out of the brain and only allow for short (e.g., < 30 minutes) durations of seizure control when given intermittently. Therefore, lorazepam is the preferred IV benzodiazepine for acute seizure control. For patients diagnosed with status epilepticus, drugs with a short CNS duration of action are desirable for administration as a continuous infusion, allowing for rapid titration and neurological assessments. Tables 2 and 3 summarize pharmacokinetic and pharmacodynamic characteristics of benzodiazepines in the serum and CNS, respectively.

Renal and hepatic function should also be considered, especially if a benzodiazepine is to be given as a continuous IV infusion or frequently enough that accumulation may occur. Diazepam, midazolam, and clobazam are metabolized by the liver via CYP3A4 to their active metabolites, so caution should be used in patients with hepatic dysfunction as their duration of action may be prolonged [53]. Drug–drug interactions should also be considered as agents such as voriconazole, fluconazole, and amiodarone will inhibit the activity of CYP3A4 while primidone, phenytoin, phenobarbital, and rifampin will induce its activity [53]. In patients with renal dysfunction, the active metabolite of midazolam may accumulate over time, so both hepatic and renal function should be considered if using this agent as a continuous infusion over an extended duration of time.

4. Administration Route Comparisons

When considering which route of administration is best, the benefits and limitations of each route should be considered. The intravenous route of administration provides the fastest onset of action with 100% bioavailability, but its application requires higher training skills and a longer time to achieve compared to other routes. Both lorazepam and diazepam IV formulations contain propylene glycol, which may cause serious side effects such as metabolic acidosis and renal insufficiency and is incompatible with most IV fluids. Lorazepam 2 mg/mL solution for injection contains 80% propylene glycol and diazepam 5 mg/mL solution for injection contains 40% propylene glycol [54]. This becomes a more important consideration when these drugs are given as a continuous IV infusion or are frequently administered. Patients with renal dysfunction are more susceptible to the accumulation of propylene glycol and its toxic effects.

Intramuscular injection absorption might be altered based on the needle size and the weight of the patient while buccal routes provide rapid absorption. However, the buccal route of administration may be challenging in patients with convulsive seizures.
absorption and a large amount of drug can be administered rectally but it may cause local irritation and is inconvenient for adult patients. The intranasal route is a more attractive option than rectal in the adolescent and adult patient for these reasons. The advantages and disadvantages of each route of administration are described in Table 4.

Table 4. Administration route advantages and disadvantages [55–64].

| Route              | Advantages                                                                 | Disadvantages                                                                 |
|--------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Intravenous        | • Fastest onset of action                                                 | • Highly trained individuals required to administer                         |
|                    | • No bioavailability concerns                                             | • May require physical restraint                                             |
|                    | • Bypass first-pass metabolism                                            | • Injection site irritation, extravasation, or infection                      |
|                    | • Large volume can be administered                                        | • Development of tolerance with continuous infusions                         |
|                    | • Reliable route for sedated or comatose patients                          |                                                                              |
| Intramuscular      | • Bypass first-pass metabolism                                            | • Trained individuals required to administer                               |
|                    | • Prolonged action                                                         | • May require physical restraint                                             |
|                    | • Easily administered                                                      | • Painful                                                                     |
|                    | • Rapid absorption                                                        | • Variable absorption                                                        |
|                    | • Bypass first-pass metabolism                                            | • Injection site irritation or infection                                      |
|                    | • Direct drug delivery to blood-brain-barrier                              | • Limited volume can be administered (2–5 mL)                                |
| Intranasal         | • Rapid absorption                                                        | • Small volume (<0.2 mL) hard to measure                                     |
|                    | • Bypass first-pass metabolism                                            | • Short retention time                                                       |
|                    | • Low risk of infection                                                    | • Nasal discharge may alter the absorption                                   |
| Buccal and Sublingual | • Rapid absorption                                                        | • Nasal irritation                                                           |
|                    | • Bypass first-pass metabolism                                            | • Variable absorption                                                        |
|                    | • Low risk of infection                                                    | • Unpalatable                                                                 |
| Rectal             | • Bypass first-pass metabolism                                            | • Challenging to place and maintain in the correct location                 |
|                    | • Ease of administration in infant emergencies                             | • Risk of aspiration                                                         |
|                    | • Low risk of infection                                                    | • Rectal irritation or proctitis with ulceration                             |
|                    |                                                                          | • Less convenient for adults                                                 |

To overcome some of the challenges of IV, IM, and PR routes of administration, benzodiazepine IN sprays were developed. Nayzilam® (IN midazolam) and Valtoco® (IN diazepam) are the most recently approved benzodiazepine products. These products have similar administration instructions and costs, but Nayzilam® might be preferred in patients with a higher seizure frequency as the second dose may be administered after 10 minutes and used for one seizure cluster every 3 days [26]. The second dose of Valtoco® may be applied after 4 hours, but should not be used for another seizure cluster until 5 days later [22].

5. Evidence for Routes of Administration

To determine if various routes of administration are equally effective, several studies have been conducted. With rectal diazepam being the most studied route of administration in the outpatient setting and intravenous benzodiazepines being the drug of choice in the inpatient setting, many of these studies have used rectal and IV administrations as a comparator group for alternative routes. The evidence for alternative routes of administration is summarized in Table 5 and provides guidance in the decision-making process for identifying safe, effective, and convenient benzodiazepine routes of administration for patients in both the in- and outpatient settings.
Table 5. Evidence supporting alternative routes of benzodiazepines administration.

| Intranasal and Rectal Formulation Trials | Author/Year | Design (Type of Seizure) | Setting | Sample | Interventions | Results |
|-----------------------------------------|-------------|--------------------------|---------|--------|---------------|---------|
| Jain et al. 2016 [65]                    | Systematic review and meta-analysis (no specific type of seizure) | Emergency department | Adult and pediatric; two randomized open-label trials (N = 91) | IN midazolam (0.2 mg/kg) Rectal diazepam (0.3–0.5 mg/kg) | IN midazolam is superior to rectal diazepam in terminating seizures within 10 min (RR 1.14; 95% CI, 1.05–1.25) |
| Holsti et al. 2010 [16]                  | Randomized single-blind trial (no specific type of seizure) | Outpatient Pediatrics (N = 92) | Rectal diazepam (0.2 mg/kg) IN midazolam (0.2 mg/kg) | Time to seizure cessation after drug administration was not significantly different between IN midazolam and rectal diazepam (3 vs. 4.3 min, p = 0.09) |
| Haan et al. 2010 [66]                    | Cross-sectional (no specific type of seizure) | Residential epilepsy center Adults (N = 21) | Rectal diazepam (10 mg) | Both have similar success rate (82% vs. 89%, p = 0.57) and time to seizure termination (4.6 vs. 4.3 min, p = 0.6) |

| Intramuscular and Rectal Formulation Trials | Author/Year | Design (Type of Seizure) | Setting | Sample | Doses | Results |
|---------------------------------------------|-------------|--------------------------|---------|--------|-------|---------|
| Momen et al. 2015 [67]                      | Randomized open-label trial (status epilepticus) | Emergency department | Pediatrics (N = 100) | IM midazolam (0.3 mg/kg) Rectal diazepam (0.5 mg/kg) | Both have a similar success rate in seizure control, but midazolam is faster to achieve seizure cessation after drug administration (2.17 vs. 1.1 min, p < 0.001) |
| Lamson et al. 2011 [39]                     | Pharmacokinetic study (healthy subjects) | - | Adults (N = 48) | - | Similar bioavailability, but rectal diazepam had a faster time to maximum concentration (0.17–1.00 h vs. 0.25–2.00 h) |

| Buccal and Rectal Formulation Trials | Author/Year | Design (Type of Seizure) | Setting | Sample | Doses | Results |
|-------------------------------------|-------------|--------------------------|---------|--------|-------|---------|
| Jain et al. 2016 [65]               | Systematic review and meta-analysis (no specific type of seizure) | Mostly in the emergency department | Pediatric and adult patients of 7 randomized clinical trials | Buccal midazolam (0.25–0.5 mg/kg) Rectal diazepam (0.5 mg/kg) | Buccal midazolam has a significantly higher rate of seizure cessation within 10 min compared to rectal diazepam (RR 1.14; 95% CI, 1.06–1.24; p = 0.0008) |
| Nakken and Lossius, 2011 [68]       | Quasi-randomized trial (status epilepticus) | Residential institution | Adults (N = 22) | Buccal midazolam (mean 15.5 mg) Rectal diazepam (mean 26 mg) | Buccal midazolam has a significantly shorter time to convulsive status epilepticus control (2.8 vs. 5 min, p = 0.012) |
| Rogawski et al. 2020 [69]           | Pharmacokinetic study (no specific type of seizure) | - | Adults (N = 28) | - | Buccal diazepam is less variable in reaching the maximum concentration compared to rectal diazepam (buccal geometric SD [GSD] 136.12–306.49 and rectal GSD 87.71–508.63), but the time buccal formulation takes to reach maximum concentration is longer than the rectal formulation (1.0 and 0.52 h, p < 0.05) |

| Other Oral Formulations Trials | Author/Year | Design (Type of Seizure) | Setting | Sample | Doses | Results |
|--------------------------------|-------------|--------------------------|---------|--------|-------|---------|
| Troester et al. 2010 [70]        | Cross-sectional home response from caregivers (no specific type of seizure) | Outpatient | Pediatrics (N = 38) | Clonazepam oral disintegrating tablet (0.25–2 mg) | Clonazepam achieved seizure control within 10 min for all the patients (74% within 5 min), and 69% of the patients who used rectal diazepam previously felt oral clonazepam was as equal or more effective than rectal diazepam |
| Conry et al. 2009 [71]           | Randomized, double-blind multicenter trial (drop vs. nondrop seizures, repetitive seizures were recorded) | Outpatient | Adults and pediatric (N = 68) | Clonazepam oral tablet (0.25 mg/kg/day vs. 1 mg/kg/day) | Patients received daily doses of clobazam. In both drop and nondrop seizures, high-dose significantly reduced seizure frequency compared to low-dose (p = 0.0001 and p = 0.0222, respectively) |
| Feely et al. 1982 [72]           | Placebo-controlled cross-over (repetitive seizures and catamenial epilepsy) | Outpatient | Adolescent (N = 14) | Clonazepam, did not specify the dosage form (20–30 mg/day) | Patients received daily doses of clobazam for 10 days around menstruation time. Thirteen patients responded favorably to clobazam. Three of them have been successfully treated to be seizure free for 3–3.5 years. No evidence of tolerance was observed |
The landmark study evaluating benzodiazepine routes of administration for adult and pediatric patients with status epilepticus is the RAMPART trial [12]. This study demonstrated noninferiority of IM midazolam and IV lorazepam for status epilepticus, although time from drug administration to seizure cessation is slower with IM midazolam than IV lorazepam. IM midazolam has a better pharmacokinetic profile as compared to IM lorazepam and IM diazepam, and it does not contain propylene glycol in its formulation. The weight of the patient should be considered when dosing IM midazolam as patients with a higher body mass index have a higher rate of failing IM treatment [79]. None of the studies on routes of IM administration to date have compared patients based on

| Author | Design (Type of Seizure) | Settings | Sample | Doses | Results |
|--------|--------------------------|----------|--------|-------|---------|
| Malu et al. 2014 [73] | Randomized open-label multicenter trial (status epilepticus) | Emergency department | Pediatrics (N = 436) | Sublingual lorazepam (0.1 mg/kg) | Sublingual lorazepam is less effective in stopping seizures within 10 min compared to rectal diazepam (56%—79%, p < 0.001), and the treatment failure was higher in the lorazepam group (OR = 2.95, 95% CI = 1.91–4.55) |
| Welch et al. 2015 [74] | Randomized double-blind multicenter trial (status epilepticus) | Emergency department | Pediatrics (N = 120) | IM midazolam (0.5 mg/kg) | IM midazolam have similar efficacy to IV lorazepam in stopping seizure before emergency department arrival (68.3% in IM midazolam vs. 71.6% in lorazepam) and (risk difference = −3.3%; 99% CI −24.9% to 18.2%) |
| Portela et al. 2015 [75] | Randomized open-label trial (no specific type of seizure) | Emergency department | Pediatrics (N = 32) | IM midazolam (0.5 mg/kg) | The time from admission to seizure termination was shorter in the IM midazolam group (7.3 vs. 10.6 min; p < 0.006), and IV placement was unsuccessful in 25% of patients in the IV group IM midazolam was noninferior to IV lorazepam with regard to the rate of seizure control without the need for rescue therapy (73.4% vs. 63.4% [95% CI, 4.0–16.1; p < 0.001]), and the total time to seizure cessation from randomization was similar between both groups |
| Silbergleit et al. (RAMPART) 2012 [12] | Randomized double-blind multicenter trial (status epilepticus) | Emergency department | Adults and pediatrics (N = 893) | IM midazolam (5–10 mg) | IN midazolam demonstrated a significantly shorter time to seizure termination than IV diazepam (3 vs. 8.5 min; p = 0.003) |

| Author | Design (Type of Seizure) | Settings | Sample | Doses | Results |
|--------|--------------------------|----------|--------|-------|---------|
| Inokuchi et al. 2015 [76] | Retrospective cohort study (status epilepticus) | Emergency department | Adults (N = 19) | IN diazepam (10 mg) | IN midazolam is similar to IV diazepam in seizure cessation within 10 min (RR 1.00; 95% CI, 0.93–1.06). However, the time to seizure control after the presentation to the emergency department was shorter in the IN midazolam group (mean difference = 5.23 min; 95% CI, −9.55 to −0.90) |
| Jain et al. 2016 [65] | Systematic review and meta-analysis (no specific type of seizure) | Emergency department | Pediatric patients of 4 randomized clinical trials | IN midazolam (0.2 mg/kg) | IN midazolam demonstrated a significantly shorter time to seizure termination than IV diazepam (3 vs. 9.5 min; p < 0.001). However, time to seizure control after the presentation to the emergency department was shorter in the IN midazolam group (mean difference = 5.23 min; 95% CI, −9.55 to −0.90) |

| Author | Design (Type of Seizure) | Settings | Sample | Doses | Results |
|--------|--------------------------|----------|--------|-------|---------|
| Tonekaboni et al. 2012 [77] | Randomized open-label trial (status epilepticus) | Emergency department | Pediatrics (N = 92) | Buccal midazolam (6–12 mos: 2.5 mg; 1–4 yrs: 5 mg; 5–9 yrs: 7.5 mg; ≥10 yrs: 10 mg) | Both medications have similar efficacy in seizure control within 10 min (68.8% vs. 70%, p = 0.09) |
| Talukdar and Chakrabarty, 2009 [78] | Randomized open-label trial (no specific type of seizure) | Emergency department | Pediatrics (N = 120) | Buccal midazolam (0.2 mg/kg) | Buccal midazolam and IV diazepam have similar efficacies in controlling any type of seizure within 5 min of drug administration (85% vs. 93.3%, p = 0.142). However, it took buccal midazolam a shorter time to control the seizure after the presentation to the emergency department compared to IV diazepam (p = 0.004) |
weight and this might contribute to the success and failure of IM therapy. Overall, IM and IV benzodiazepines appear to be equally effective in controlling seizures, but the IV route works faster and is therefore the preferred route of administration in the acute setting for trained personnel. In cases of drug shortages or for patients without IV access, IM midazolam is definitely a viable option for the treatment of acute seizures and status epilepticus.

Studies of intranasal benzodiazepines in the past have utilized a non-FDA approved product, the intravenous injectable solution administered with an atomizer, compared to the newer commercially available IN products. No studies to date have compared the newest IN products with the off-label use of the IV solution administered intranasally. Older studies using the IV diazepam solution intranasally have shown it to be effective and that it sometimes more rapidly terminates seizures than IV and rectal diazepam, possibly due to faster administration times [76]. In a meta-analysis, IN midazolam showed no significant difference in seizure cessation within 10 minutes when it was compared to IV diazepam [65]. However, the time to seizure control after the presentation to the emergency department was shorter in the IN midazolam group. It is recommended that the volume for intranasal drug not exceed 0.2 mL [59]; however, most of the studies evaluated exceeded that limit. Intranasal diazepam has higher bioavailability compared to the midazolam injectable solution given intranasally, which may also affect the efficacy of the total dose if not completely absorbed. Despite these limitations, the intranasal route of administration demonstrates a similar efficacy to intravenous benzodiazepine therapy in seizure control.

There is limited evidence that compares buccal benzodiazepine administration to IV for seizure control, with most of these studies being conducted in the pediatric population. Some countries have buccal midazolam products available on the market while others use the intravenous injectable solution as an alternative for administration via this route [65]. Buccal midazolam and diazepam are effective for acute seizure treatment and have demonstrated similar efficacy to IV diazepam [77,78]. It is important to note that some patients in these studies received commercially available buccal midazolam (Epistatus®) while others received injectable midazolam buccally, which may have impacted the results. Buccal diazepam has less variability in achieving maximum concentrations compared to rectal diazepam, but the time to reach maximum concentrations is longer [69,80]. One important factor to consider is that food, saliva secretion, and local pH may alter the absorption of the buccal films and it may reduce their maximum concentration [60]. Buccal diazepam is currently in phase 3 investigational drug trials in the United States [52].

Studies comparing oral routes of administration to control emergent seizure attacks have also been conducted; although these routes are usually prescribed for patients with panic attacks. In regard to efficacy and convenience, patients with a history of rectal diazepam use reported that they felt oral clonazepam was equally or more effective than rectal diazepam, and caregivers preferred this route over rectal as well [70]. For pediatric convulsive status epilepticus, sublingual lorazepam was found to be less effective in stopping seizures within 10 minutes of administration compared to rectal diazepam, and the odds of treatment failure was higher in the lorazepam group [73]. They also observed a high potential for failure for oral therapies in patients with convulsive seizures due to the risk of aspiration or incomplete absorption due to salivation [73]. Although oral routes of administration are an option to manage patients with seizure attacks; in patients presenting with convulsive seizures, this route is not practical.

6. Benzodiazepine Routes and Adverse Events

Several adverse events are associated with benzodiazepine administration, including hypotension, confusion, sedation, and respiratory failure. However, a delay in benzodiazepines administration lowers the potency of benzodiazepines due to the changes in receptors, including GABA downregulation and N-methyl-D-aspartate (NMDA) upregulation, after a prolonged seizure [81,82]. A multicenter prospective clinical trial of pediatric
patients found that a delay of benzodiazepine administration for more than 10 minutes resulted in higher chances of requiring continuous infusion therapy (adjusted odds ratio (AOR), 1.8; 95% CI, 1.01–3.36; \( p = 0.047 \)), longer convulsion duration (AOR 2.6; 95% CI, 1.38–4.88; \( p = 0.003 \)), more frequent hypotension (AOR 2.3; 95% CI, 1.16–4.63; \( p = 0.02 \)), and death (AOR, 11.0; 95% CI, 1.43 to ∞; \( p = 0.02 \)) [83]. In adults, 22.5% of patients who received placebo therapy experienced either hypotension, cardiac dysrhythmia, or a respiratory problem that required an intervention compared to 10.6% in the IV lorazepam group and 10.3% in the IV diazepam group [7].

Chronic or continuous exposure to benzodiazepines may increase the risk of developing tolerance leading to decreased efficacy [63,64]. This is concerning in patients receiving continuous infusion benzodiazepines for status epilepticus, and will require increasing doses for continued seizure control, but it may not occur with intermittent doses of benzodiazepines to control acute repetitive seizure episodes [9,10,84]. Once maximum doses of the selected benzodiazepine have been reached, other antiseizure drugs may need to be initiated to control seizures [9,10].

In summary, a delay in the administration of a benzodiazepine agent will decrease the ability to control a seizure and may lead to death. The risk of withholding a benzodiazepine from a patient with a seizure far outweighs the adverse effects. Some of the benzodiazepine adverse events associated with the various routes of administration are summarized in Table 6.

| Adverse Event                  | Lorazepam IV | Midazolam | Diazepam | Clobazam |
|-------------------------------|--------------|-----------|----------|----------|
| Respiratory complication      | 4.4–17.6%    | 10.8–14.6%| 8%       | 1.2–6.4% |
| Hypotension                   | 1.5–25.8%    | 1.4%      | <1–21.8% | 15–31.6% |
| Cardiac arrhythmia            | 7.2%         | <1%       | <1%      | <1%      |
| Dizziness/ataxia              | 7%           | <1%       | <1%      | <1%      |
| Somnolence/drowsiness         | 1.5%         | <1%       | 10–68%   | 23%      |
| Local reaction                | <1%          | 11.5–29%  | <1–21%   | 14%      |

* Formulations that contain propylene glycol have a higher risk of metabolic acidosis, renal insufficiency, hypotension, and cardiac arrhythmias. IM, intramuscular; IN, intranasal; IV, intravenous; PR, rectal.

7. Summary

In the outpatient setting, treatment of acute repetitive seizures was previously limited to rectal diazepam, whereas in the inpatient setting IV benzodiazepines remain the route of choice for seizure emergencies. New studies have compared rectal diazepam to IN midazolam, IM midazolam, buccal midazolam, IM diazepam, buccal diazepam, sublingual lorazepam, and an orally disintegrating clonazepam tablet. The limitations of these trials include the use of intravenous injectable solutions for IN and buccal administration and small sample sizes. Intranasal and buccal routes appear to be equally effective and more rapidly administered than rectal diazepam. The choice of the route of administration in the outpatient setting should consider the logistical challenges of administration, patient and caretaker comfort, and cost.

In the inpatient setting, the IV route remains the preferred route for benzodiazepine administration, and lorazepam is the preferred agent due to its longer CNS half-life. Alternative routes of administration for benzodiazepines include IM, IN, and buccal administration and these may be used in patients without IV access. All routes of benzodiazepine administration are effective for acute seizure management, but pharmacokinetic
characteristics, patient comorbidities, and concomitant medications should also be considered in the inpatient setting when choosing the specific agent and when multiple doses are required.

Benzodiazepines may cause adverse events which vary in frequency depending on the route of administration. Despite this, a delay or inappropriate dosing of benzodiazepine therapy to control seizures can be detrimental and may lead to poor outcomes.

**Author Contributions:** Conceptualization, S.A., M.S., G.M.B.; investigation, S.A.; writing—original draft preparation, S.A.; writing—review and editing, S.A., M.S., G.M.B.; visualization, S.A., M.S., G.M.B.; supervision, G.M.B.; project administration, S.A., G.M.B.; funding acquisition, G.M.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** The contents of this manuscript were developed in part under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant number 90AR5025). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policies of NIDILRR, ACL, and HHS, and you should not assume endorsement by the Federal Government.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** Gretchen M. Brophy is a speaker/consultant for UCB and a consultant for Sage and Ceribell. The other authors declare no conflict of interest.

**References**

1. Towne, A.R.; Pellock, J.M.; Ko, D.; DeLorenzo, R.J. Determinants of mortality in status epilepticus. *Epilepsia* 1994, 35, 27–34, doi:10.1111/j.1528-1157.1994.tb02908.x.

2. Logsdail, S.J.; Toone, B.K. Post-ictal psychoses. A clinical and phenomenological description. *Br. J. Psychiatry Ment. Sci.* 1988, 152, 246–252, doi:10.1192/bjp.152.2.246.

3. Haut, S.R.; Shinnar, S.; Moshé, S.L. Seizure clustering: Risks and outcomes. *Epilepsia* 2005, 46, 146–149, doi:10.1111/j.0013-9580.2005.29004.x.

4. Haut, S.R.; Shinnar, S.; Moshé, S.L.; O’Dell, C.; Legatt, A.D. The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. *Epilepsia* 1999, 40, 1832–1834, doi:10.1111/j.1528-1157.1999.tb01607.x.

5. Sillanpää, M.; Schmidt, D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. *Brain J. Neurol.* 2001, 131, 938–944, doi:10.1093/brain/awr137.

6. Alldredge, B.K.; Gelb, A.M.; Isaacs, S.M.; Corry, M.D.; Allen, F.; Ulrich, S.; Gottwald, M.D.; O’Neil, N.; Neuhaus, J.M.; Segal, M.R.; et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. *N. Engl. J. Med.* 2001, 345, 631–637, doi:10.1056/NEJMoa002141.

7. Silbergleit, R.; Lowenstein, D.; Durkalski, V.; Conwit, R. Lessons from the RAMPART study—And which is the best route of administration of benzodiazepines in status epilepticus. *Epilepsia* 2013, 54, 74–77, doi:10.1111/epi.12284.

8. Brophy, G.M.; Bell, R.; Claassen, J.; Alldredge, B.; Bleck, T.P.; Glauser, T.; Laroche, S.M.; Riviello, J.J.; Shutter, L.; Sperling, M.R.; et al. Neurocritical care society status epilepticus guidelines writing committee. Guidelines for the evaluation and management of status epilepticus. *Neurocrit. Care* 2012, 17, 3–23, doi:10.1007/s12028-012-9695-z.

9. Glauser, T.; Shinnar, S.; Gloss, D.; Alldredge, B.; Arya, R.; Bainbridge, J.; Bare, M.; Bleck, T.; Dodson, W.E.; Garrity, L.; et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. *Epilepsie Curr.* 2016, 16, 48–61, doi:10.5698/1535-7597-16.1.48.

10. García-López, B.; Gómez-Menéndez, A.I.; Vázquez-Sánchez, F.; Pérez-Cabo, E.; Isidro-Mesas, F.; Zabalegui-Pérez, A.; Muñoz-Siscart, I.; Lloria-Gil, M.C.; Soto-Cámaro, R.; González-Bernal, J.J.; et al. Electroconvulsive therapy in super refractory status epilepticus: A case series with a defined protocol. *Int. J. Environ. Res. Public Health* 2020, 17, 4023, doi:10.3390/ijerph17114023.

11. Silbergleit, R.; Durkalski, V.; Lowenstein, D.; Conwit, R.; Pancioli, A.; Palesch, Y.; Barsan, W. Intramuscular versus intravenous therapy for prehospital status epilepticus. *N. Engl. J. Med.* 2012, 366, 591–600, doi:10.1056/NEJMoa1107494.

12. Riva, A.; Iapadre, G.; Grasso, E.A.; Balagura, G.; Striano, P.; Verrotti, A. Intramuscular midazolam for treatment of status epilepticus. *Expert Opin. Pharmacother.* 2021, 22, 37–44, doi:10.1080/14656566.2020.1810236.

13. Leppik, I.E.; Patil, S.I. Intramuscular and rectal therapies of acute seizures. *Epilepsy Behav.* 2015, 49, 307–312, doi:10.1016/j.yebeh.2015.05.001.
J. Clin. Med. 2020, 11, 1754

41. Chiaretti, A.; Barone, G.; Rigante, D.; Ruggiero, A.; Pierri, F.; Barbì, E.; Barone, G.; Riccardi, R. Intranasal lidocaine and midazolam for procedural sedation in children. Arch. Dis. Child. 2011, 96, 160–163, doi:10.1136/adc.2010.188433.

42. Greenblatt, D.J.; Shader, R.I.; Franke, K.; MacLaughlin, D.S.; Harmatz, J.S.; Allen, M.D.; Werner, A.; Woo, E. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J. Pharm. Sci. 1979, 68, 57–63, doi:10.1002/jps.2600680119.

43. Wermeling, D.P.; Miller, J.L.; Archer, S.M.; Manaligod, J.M.; Rudy, A.C. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J. Clin. Pharmacol. 2001, 41, 1225–1231, doi:10.1177/009127010122012779.

44. Lamson, M.J.; Sitki-Green, D.; Wannarka, G.L.; Mesa, M.; Andrews, P.; Pellock, J. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: A phase I, randomized, open-label, single-dose, crossover, single-centre study. Clin. Drug Investig. 2011, 31, 585–597, doi:10.2165/11590520-00000000-00000.

45. Güzurarson, S.; Gudbrandsson, F.K.; Jónsson, H.; Hebgård, E. Intranasal administration of diazepam aiming at the treatment of acute seizures: Clinical trials in healthy volunteers. Biol. Pharm. Bull. 1999, 22, 425–427, doi:10.1248/bpb.22.425.

46. Björkman, S.; Rigemar, G.; Idvall, J. Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. Br. J. Anaesth. 1997, 79, 575–580, doi:10.1093/bja/79.5.575.

47. Veldhorst-Janssen, N.M.L.; Fiddelers, A.A.A.; van der Kuy, P.-H.M.; Neef, C.; Marcus, M.A.E. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Expert Opin. Drug delivery 2009, 31, 2954–2987, doi:10.1016/j.ejdr.2009.12.015.

48. Allonen, H.; Ziegler, G.; Klotz, U. Midazolam kinetics. Clin. Pharmacol. Ther. 1981, 30, 653–661, doi:10.1038/clpt.1981.217.

49. Horn, E.; Nesbit, S.A. Pharmacology and pharmacokinetics of sedatives and analgesics. Gastrointest. Endosc. Clin. N. Am. 2004, 14, 247–268, doi:10.1016/j.ge.2004.01.001.

50. Von Blomberg, A.; Kay, L.; Knake, S.; Fuest, S.; Zöllner, J.; Reif, P.S.; Herrmann, E.; Balaban, Ü.; Schubert-Bast, S.; Rosenow, F.; et al. Efficacy, tolerability, and safety of concentrated intranasal midazolam spray as emergency medication in epilepsy patients during video-EEG monitoring. CNS Drugs 2020, 34, 545–553, doi:10.1007/s40263-020-00720-w.

51. Nishiya, T.; Tamai, H.; Hanaoka, K. Serum and cerebrospinal fluid concentrations of midazolam after epidural administration in dogs. Anesth. Analg. 2003, 96, 159–162, doi:10.1213/01.nrl.0000066113.53262.17.

52. Nishiya, T.; Tamai, H.; Hanaoka, K. Cerebrospinal-fluid concentrations of midazolam and its metabolites in man. Acta Pharmacol. Toxicol. 1975, 36, 328–334, doi:10.1111/j.1600-0773.1975.tb00800.x.

53. Arroliga, A.C.; Shehab, N.; McCarthy, K.; Gonzalez, J.P. Relationship of continuous infusion lorazepam to serum propylene glycol concentrations in critically ill adults. Crit. Care Med. 2004, 32, 1709–1714.

54. Jain, K.K. Drug delivery systems—An overview. In Drug Delivery Systems: Methods in Molecular Biology™; Jain, K.K., Ed.; Humana Press: Totowa, NJ, USA, 2008; pp. 1–50, doi:10.1007/978-1-59745-210-6_1.

55. Polania Gutierrez, J.J.; Munakomi, S. Intranasal Injection; StatPearls Publishing: Treasure Island, FL, USA, 2020.

56. Soliman, E.; Ranjan, S.; Xu, T.; Lee, C.; Harker, A.; Barrera, A.; Geddes, J. A narrative review of the success of intranasal gluteal injections and its impact in psychiatry. Bio Des. Manuf. 2018, 1, 161–170, doi:10.1080/24724018.2018.1385210.

57. Erdö, F.; Bors, L.; Farkas, D.; Bajza, Á.; Gödöcs, P.; et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018, 143, 155–170, doi:10.1016/j.brainresbull.2018.10.009.

58. Lochhead, J.J.; Thorne, R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 2012, 64, 614–628, doi:10.1016/j.addr.2011.11.002.

59. Chinna Reddy, P.; Chaitanya, K.S.C.; Madhusudan Rao, Y. A review on bioadhesive buccal drug delivery systems: Current status of formulation and evaluation methods. DARU J. Pharm. Sci. 2011, 19, 385–403.

60. Fathier, S.I.; Rathbone, M.J.; Senel, S. Current status and the future of buccal drug delivery systems. Expert Opin. Drug Deliv. 2008, 5, 531–542, doi:10.1517/17425247.5.5.531.

61. Jain, K.K. An overview of drug delivery systems. In Drug Delivery Systems: Methods in Molecular Biology; Jain, K.K., Ed.; Springer: New York, NY, USA, 2020; pp. 1–54, doi:10.1007/978-1-4939-9798-5_1.

62. Löschler, W.; Kundert, C.; Höckendorf, D.; Ebert, U. Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison of diazepam, clonazepam, clobazam and abacemol. J. Pharmacol. Exp. Ther. 1996, 279, 561–572.

63. Kundert, C.; Wiaz, P.; Höckendorf, D.; Löschler, W. Anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abacemol. J. Pharmacol. Exp. Ther. 1995, 275, 693–702.

64. Chan, V.O.; Colville, J.; Persaud, T.; Buckley, O.; Hamilton, S.; Torreggiani, W.C. Intramuscular injections into the buttocks: Are they truly intramuscular? Eur. J. Radiol. 2006, 58, 480–484, doi:10.1016/j.ejrad.2006.01.008.

65. Inokuchi, R.; Ohashi-Fukuda, N.; Nakamura, K.; Wada, T.; Gunshin, M.; Kitsuta, Y.; Nakajima, S.; Yahagi, N. Comparison of intranasal and intravenous diazepam on status epilepticus in stroke patients: A retrospective cohort study. Medicine 2015, 94, e555, doi:10.1097/MD.0000000000000555.

66. Jain, P.; Sharma, S.; Dua, T.; Barbui, C.; Das, R.R.; Aneja, S. Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis. Epilepsia Res. 2016, 122, 47–55, doi:10.1016/j.eplepsres.2016.02.006.

67. Tonekaboni, S.-H.; Shamsabadi, F.M.; Anvari, S.-S.; Mazrooei, A.; Gholifah, M. A comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children. Iran. J. Pediatr. 2012, 22, 303–308.
J. Clin. Med. 2021, 10, 1754

69. Talukdar, B.; Chakrabarty, B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: A randomized controlled trial. *Brain Dev.* 2009, 31, 744–749, doi:10.1016/j.braindev.2008.11.006.

70. Rogawski, M.A.; Heller, A.H.; Farrow, S.; Jung, C.; Klein, P.; Boudreault, S.; Slatko, G. Pharmacokinetics of diazepam buccal film in adult patients with epilepsy: Comparison with diazepam rectal gel (4437). *Neurology 2020*, 94, 4437.

71. Rogawski, M.A.; Heller, A.H. Diazepam buccal film for the treatment of acute seizures. *Epilepsia Behav.* 2019, 101, 106537, doi:10.1016/j.yebeh.2019.106537.

72. Troester, M.M.; Hastriter, E.V.; Ng, Y.-T. Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures: *J. Child Neurol.* 2010, doi:10.1177/0883073810368312.

73. Malu, C.K.K.; Kambah, D.M.; Walker, T.D.; Mukampunga, C.; Musalou, E.M.; Kokolomani, J.; Mayamba, R.M.K.; Wilmshurst, J.M.; Dubru, J.-M.; Misson, J.-P. Efficacy of sublingual lorazepam versus intrarectal diazepam for prolonged convulsions in Sub-Saharan Africa. *J. Child Neurol.* 2014, 29, 895–902, doi:10.1177/0883073814493501.

74. Haan, G.-D.; Geest, P.V.D.; Doelman, G.; Bertram, E.; Edelbroek, P. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. *Epilepsia* 2010, 51, 478–482, doi:10.1111/j.1528-1167.2009.02333.x.

75. Momen, A.A.; Azizi Malamiri, R.; Nikkhah, A.; Jafari, M.; Fayezi, A.; Riahi, K.; Maraghi, E. Efficacy and safety of intramuscular midazolam versus rectal diazepam in controlling status epilepticus in children. *Eur. J. Paediatr. Neurol.* 2015, 19, 149–154, doi:10.1016/j.ejpn.2014.11.007.

76. Nakken, K.O.; Lossius, M.I. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. *Acta Neurol. Scand.* 2011, 124, 99–103, doi:10.1111/j.1600-0404.2010.01474.x.

77. Conry, J.A.; Ng, Y.-T.; Paolicchi, J.M.; Kernitsky, L.; Mitchell, W.G.; Ritter, F.J.; Collins, S.D.; Tracy, K.; Kormany, W.N.; Abdulnabi, R.; et al. Clobazam in the treatment of lennox-gastaut syndrome. *J. Child Neurol.* 2016, 31, 1274–1282, doi:10.1177/0883073815604009.

78. Leppik, I.E.; Derivan, A.T.; Homan, R.W.; Walker, J.; Ramsay, R.E.; Patrick, B. Double-blind study of lorazepam and diazepam in the treatment of status epilepticus. *Epilepsia* 1983, 24, 1452–1454.

79. Welles, J.W.; Meng, T.-C.; van Ess, P.J.; Detrynieck, K.; Sequeira, D.J.; Pullman, W.E. Safety and efficacy of midazolam nasal spray in the outpatient treatment of seizures with seizure clusters: An open-label extension trial. *Epilepsia* 2019, 60, 1809–1819, doi:10.1111/epi.16300.

80. Treiman, D.M.; Meyers, P.D.; Walton, N.Y.; Collins, J.F.; Colling, C.; Rowan, A.J.; Handforth, A.; Faught, E.; Calabrese, V.P.; Uthman, B.M.; et al. A comparison of four treatments for generalized convulsive status epilepticus. *Veterans affairs status epi-...
93. Dreifuss, F.E.; Rosman, N.P.; Cloyd, J.C.; Pellock, J.M.; Kuzniecky, R.I.; Lo, W.D.; Matsuo, F.; Sharp, G.B.; Conry, J.A.; Bergen, D.C.; et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. *N. Engl. J. Med.* 1998, 338, 1869–1875, doi:10.1056/NEJM199806253382602.

94. Kutlu, N.O.; Dogrul, M.; Yakinci, C.; Soylu, H. Buccal midazolam for treatment of prolonged seizures in children. *Brain Dev.* 2003, 25, 275–278, doi:10.1016/s0387-7604(02)00230-9.